Syndax Pharmaceuticals Inc
SNDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.02B
Close$
$-0.80
103.6% downside
Current Fair Value
103.6% downsideOvervalued by 103.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.02 Billion |
|---|---|
| Enterprise Value | $1.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.37 |
| Outstanding Shares | 86,621,003 |
Return
| Return on Equity | -584.42% |
|---|---|
| Return on Assets | -51.46% |
| Return on Invested Capital | -44.23% |
Valuation & Multiples
| P/E Ratio | -8.14 |
|---|---|
| PEG | 16.38 |
| Price to Sales | 11.03 |
| Price to Book Ratio | 22.05 |
| Enterprise Value to Revenue | 8.7 |
| Enterprise Value to EBIT | -11.05 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$73.98 M
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$79.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 66.40% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.90%▼ 113.81% |
|---|---|
| Total Invested | $17.09M▼ 99.26% |
| Investors Holding | 17▼ 243.00% |
ESG Score
No data
About Syndax Pharmaceuticals Inc
CEO: Arlene Morris